--- title: InsightRX Presents Research Evaluating Effectiveness of Model-Informed Precision Dosing for Heparin at Annual Anticoagulation Forum Meeting description: InsightRX published simulations using model-informed precision dosing of heparin resulting in higher target dosage attainment compared to nomogram. image: https://blog.insight-rx.com/hubfs/Anti-Coag-Forum-1.png --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://blog.insight-rx.com/) - For Providers - Solutions - [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd) - [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future) - Products - [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova) - [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo) - [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules) - [For Life Sciences](https://www.insight-rx.com/life-sciences) - Overview - [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences) - Products - [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova) - [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra) - Platform - [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning) - [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support) - Resources - Science - [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science) - [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications) - [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova) - Explore - [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories) - [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers) - [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software) - [Blog](https://blog.insight-rx.com/resources) - [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources) - [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership) - Company - About - [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about) - [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership) - [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board) - [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers) - [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers) - Press - [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases) - [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) [![Contact Us](https://no-cache.hubspot.com/cta/default/40041574/interactive-193831493462.png)](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574) Press Releases # InsightRX Presents Research Evaluating Effectiveness of Model-Informed Precision Dosing for Heparin at Annual Anticoagulation Forum Meeting - Published April 4, 2023 By [InsightRX Communications](https://blog.insight-rx.com/press-releases/author/insightrx) ![](https://blog.insight-rx.com/hubfs/Anti-Coag-Forum-1.png) SAN FRANCISCO, April 4, 2023 –InsightRX – which provides cloud-based precision medicine software to optimize treatment decisions – presented research comparing model-informed precision dosing (MIPD) to a hospital dosing nomogram for therapeutic heparin dosing at the 17th National Conference on Anticoagulation Therapy held April 1-3 in San Francisco. The research, titled “Anti-Xa target attainment & dose selection: comparison of pharmacokinetic model-guided dosing versus institutional practice,” was presented during a one-hour poster session on Saturday, April 1, at the San Francisco Marriott Marquis. Jonathan D. Faldasz, Pharm.D., BCPS, senior director of product and customer experience at InsightRX, was the presenter. MIPD has proven clinically beneficial in achieving therapeutic drug exposure and decreasing the need for dosing adjustment, yet there has been little research on the application of MIPD to the dosing of unfractionated heparin (UFH). An InsightRX team recently conducted a simulation from which it concluded that an initial therapeutic heparin dosing strategy using MIPD may enable more accurate dosing than would an average hospital dosing nomogram (a flow chart for calculating the correct dosage for a specific patient). Heparin is an anticoagulant used therapeutically to prevent or slow the development and growth of blood clots in people with certain medical conditions or patients undergoing high-risk medical procedures. Unfortunately,[anticoagulants have been “consistently identified as the most common cause of adverse drug events (ADEs)”](https://www.ncbi.nlm.nih.gov/books/NBK555529/) in healthcare settings. And despite advances in therapeutic heparin dosing and monitoring, determining the right dosage can be extremely challenging because each patient eliminates heparin at their own rate, based on variables such as their size, blood composition, and underlying disease state. This undermines the effectiveness of standardized dosing guidelines and introduces some risk to patients. Heparin levels below the target range for a patient can result in further and worsening clot formation, with potential for embolic organ failure, embolic stroke and death, while levels above the target range can trigger major bleeding, with serious consequences including hemorrhagic stroke, organ failure and death. It is essential, therefore, to closely monitor the effect that heparin is having on a patient.  The two most common measures of heparins activity are the antifactory-Xa assay (anti-Xa) and activated partial thromboplastic time (aPTT). InsightRX researchers conducted a digital twin study in which they assembled real-world covariate weight distributions from a sample of 2,000 de-identified adult patients from the InsightRX database. The researchers then combined that data with synthesized data generated according to inter-patient variation as defined by a model describing the pharmacokinetic/pharmacodynamics of heparin developed by [Delavenne et al](https://pubmed.ncbi.nlm.nih.gov/28510738/). An initial dose was calculated according to a typical hospital nomogram (both low and high dose) and as predicted by two pharmacokinetic (PK) models (Delavenne et al and Brunet et al) to achieve steady-state anti-Xa concentration in the desired therapeutic range of 0.3-0.7 units/mL. Results of the simulation show that initial heparin dosing using MIPD is more likely to result in target dosage attainment than would a hospital nomogram. This is significant because more accurate initial heparin dosing will reduce the number of patients whose doses must be adjusted and will minimize the likelihood of an ADE that could be life-threatening or life-changing to a patient. > “This is a promising development in improving the ability of hospitals to ensure patients receiving heparin injections are being administered safe and effective dosages,” said Sirj Goswami, CEO and co-founder of InsightRX. “Our study shows that, used with the right dosing model, MIPD can potentially be used to drive better outcomes for patients being treated with heparin.”   [conferences](https://blog.insight-rx.com/press-releases/tag/conferences) [heparin](https://blog.insight-rx.com/press-releases/tag/heparin) [anticoagulation](https://blog.insight-rx.com/press-releases/tag/anticoagulation) [AC forum](https://blog.insight-rx.com/press-releases/tag/ac-forum) #### On this page… **Connect with us to get the latest blog updates, instantly sent to your inbox** ## Dig deeper. Explore related articles and additional posts on the InsightRX blog. [Press Releases Jun 13, 2024 Northern Arizona Healthcare (NAH) Partners with InsightRX on the First Commercial Precision Dosing Model For Heparin](https://blog.insight-rx.com/press-releases/northern-arizona-healthcare-insightrx-precision-dosing-model-heparin) [Press Releases Oct 28, 2025 The Christ Hospital Health Network Pharmacy Uses New Technology to Better Serve Patients](https://blog.insight-rx.com/press-releases/christ-hospital-pharmacy-technology-improves-patient-care) [Press Releases Mar 13, 2019 InsightRX And Children's Hospital Los Angeles (CHLA) To Partner On Precision Dosing](https://blog.insight-rx.com/press-releases/chla-bestdose-partners-precision-dosing) #### What We Do ##### For Providers - [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova) - [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo) - [Drug Modules](https://www.insight-rx.com/provider/drug-modules) ##### For Life Sciences - [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova) - [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra) - [Companion Applications](https://www.insight-rx.com/life-sciences/nova#companion-applications) #### How We Do It ##### Platform - [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning) - [Integrations](https://www.insight-rx.com/platform/integrations) - [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory) - [Success & Support](https://www.insight-rx.com/platform/success-support) ##### Science - [Data Science](https://www.insight-rx.com/data-science) - [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications) #### Information ##### Resources - [Success Stories](https://www.insight-rx.com/success-stories) - [White Papers](https://www.insight-rx.com/white-papers) - [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software) - [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova) ##### Blog - [All Posts](https://blog.insight-rx.com/resources) - [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation) - [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership) #### About - [Our Story](https://www.insight-rx.com/about) - [Leadership](https://www.insight-rx.com/leadership) - [Advisory Board](https://www.insight-rx.com/advisory-board) - [Our Customers](https://www.insight-rx.com/customers) - [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases) - [Media](https://blog.insight-rx.com/press-releases?section=media) - [Careers](https://www.insight-rx.com/careers) - [Contact](https://www.insight-rx.com/contact-us) --- ![CE marking](https://blog.insight-rx.com/hubfs/ce-mark-white.svg) InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1. InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance. 740-05000-REC-01 · 08/2025 --- [![InsightRX](https://blog.insight-rx.com/hubfs/insightrx_logo_white-teal.svg)](https://www.insight-rx.com/) 548 Market Street #88083 San Francisco, CA 94104 --- © 2026 InsightRX, Inc. All rights reserved. [Privacy Policy](https://www.insight-rx.com/privacy-policy) Cookie Preferences ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "InsightRX Communications", "url" : "https://blog.insight-rx.com/press-releases/author/insightrx" }, "dateModified" : "2025-12-15T00:30:55.464Z", "datePublished" : "2023-04-04T17:26:00.000Z", "headline" : "InsightRX Presents Research Evaluating Effectiveness of Model-Informed Precision Dosing for Heparin at Annual Anticoagulation Forum Meeting", "image" : [ "https://blog.insight-rx.com/hubfs/Anti-Coag-Forum-1.png" ], "mainEntityOfPage" : { "@id" : "https://blog.insight-rx.com/press-releases/insightrx-presents-research-evaluating-effectiveness-model-informed-precision-dosing-heparin-annual-anticoagulation-forum-meeting", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.insight-rx.com/hubfs/insightrx_logo_color%20500%20x%20250-1.png" }, "name" : "InsightRX" } } ```